Aastrom Biosciences, Inc.
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
|
|
|
o
|
|
Preliminary Proxy Statement |
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
þ
|
|
Definitive Proxy Statement |
o
|
|
Definitive Additional Materials |
o
|
|
Soliciting Material Pursuant to §240.14a-12 |
Aastrom Biosciences, Inc.
(Name of Registrant as Specified in Its Charter)
Payment of filing fee (Check the appropriate box):
ý No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
(2)
|
|
Aggregate number of securities to which transaction applies: |
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which filing fee is calculated and
state how it was determined): |
(4)
|
|
Proposed maximum aggregate value of transaction:
|
(5)
|
|
Total fee paid: |
|
|
|
|
|
Fee paid previously with preliminary materials. |
|
|
Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11 (a) (2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing. |
|
|
|
(1)
|
|
Amount previously paid: |
(2)
|
|
Form, Schedule or Registration No.: |
(3)
|
|
Filing Party: |
(4)
|
|
Date Filed: |
October 11,
2007
Dear Shareholder:
Please join us for our Annual Meeting of Shareholders on
Wednesday, November 7, 2007 at 9:00 a.m. (EST), at
Aastroms offices, 24 Frank Lloyd Wright Drive, Lobby K,
Ann Arbor, Michigan 48105. You are cordially invited to attend.
The Annual Meeting of Shareholders will be webcast live for
those who are unable to attend in person. To access the webcast
of the meeting please visit our website at
www.aastrom.com and follow the link provided on the
Calendar of Events in our News section.
The enclosed Notice of Annual Meeting of Shareholders and a
Proxy Statement describe the formal business to be conducted at
the meeting.
Your vote is important. Please use this opportunity to take part
in the affairs of Aastrom Biosciences by voting on the business
to come before this meeting. After reading the Proxy Statement,
please promptly mark, sign, and return the enclosed proxy in the
prepaid envelope to assure that your shares will be represented.
Your shares cannot be voted unless you date, sign, and return
the enclosed proxy or attend the Annual Meeting in person.
Regardless of the number of shares you own, your careful
consideration of, and vote on, the matters before our
shareholders are important.
A copy of Aastroms 2007 Annual Report is also enclosed for
your information. At the Annual Meeting we will review
Aastroms activities over the past year and our plans for
the future. The Board of Directors and management team look
forward to seeing you at the Annual Meeting.
Sincerely,
George W. Dunbar, Jr.
President and Chief Executive Officer
TABLE OF CONTENTS
AASTROM
BIOSCIENCES, INC.
24 Frank Lloyd Wright Drive, Lobby
K
Ann Arbor, MI 48105
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
To Be Held November 7, 2007
|
|
|
TIME |
|
9:00 a.m. (Eastern Standard Time) on Wednesday,
November 7, 2007. |
|
PLACE |
|
Aastrom Biosciences Corporate Office |
|
|
24 Frank Lloyd Wright Drive, Lobby K |
|
|
Ann Arbor, MI 48105 |
|
ITEMS OF BUSINESS |
|
1. To elect three Class I directors for three-year terms. |
|
|
|
2. To ratify the appointment of PricewaterhouseCoopers LLP as
Aastroms independent registered public accounting firm. |
|
|
|
3. To consider such other business as may properly come before
the Annual Meeting of Shareholders and any adjournment thereof. |
|
RECORD DATE |
|
You may vote at the Annual Meeting of Shareholders if you were a
shareholder of record at the close of business on
September 14, 2007. |
|
VOTING BY PROXY |
|
If you cannot attend the Annual Meeting of Shareholders, you may
vote your shares over the internet or by telephone, or by
completing and promptly returning the enclosed proxy card in the
envelope provided. Internet and telephone voting procedures are
on your proxy card. |
|
ANNUAL REPORT |
|
Aastroms 2007 Annual Report accompanies this Notice of
Annual Meeting of Shareholders. |
By order of the Board of Directors,
Gerald D. Brennan, Jr.
Corporate Secretary, Vice President,
Administrative & Financial
Operations and Chief Financial Officer
Ann Arbor, Michigan
October 11, 2007
AASTROM
BIOSCIENCES, INC.
24 Frank Lloyd Wright Drive, Lobby
K
Ann Arbor, Michigan 48105
PROXY
STATEMENT FOR ANNUAL MEETING OF SHAREHOLDERS
The accompanying proxy is solicited by the Board of Directors of
Aastrom Biosciences, Inc., a Michigan corporation, for use at
the Annual Meeting of Shareholders to be held November 7,
2007, or any adjournment thereof, for the purposes set forth in
the accompanying Notice of Annual Meeting. The date of this
Proxy Statement is October 11, 2007, the approximate date
on which this Proxy Statement and the accompanying form of proxy
were first sent or given to shareholders. Unless the context
requires otherwise, references to we,
us, our, and Aastrom refer
to Aastrom Biosciences, Inc.
GENERAL
INFORMATION ABOUT THE MEETING, SOLICITATION AND VOTING
Annual Report. An annual report for the fiscal
year ended June 30, 2007, is enclosed with this Proxy
Statement.
What am I
voting on?
There are two proposals scheduled to be voted on at the Annual
Meeting of Shareholders:
|
|
|
|
|
Election of three directors;
|
|
|
|
Ratification of the appointment of PricewaterhouseCoopers LLP as
Aastroms independent registered public accounting firm for
fiscal year 2008; and
|
Who is
entitled to vote?
Shareholders as of the close of business on September 14,
2007 (the Record Date), may vote at the Annual
Meeting of Shareholders. You have one vote for each share of
common stock you held on the Record Date, including shares:
|
|
|
|
|
Held directly in your name as shareholder of record
(also referred to as registered shareholder);
|
|
|
|
Held for you in an account with a broker, bank or other nominee
(shares held in street name). Street name holders
generally cannot vote their shares directly and must instead
instruct the brokerage firm, bank or nominee how to vote their
shares.
|
What
constitutes a quorum?
A majority of the outstanding shares entitled to vote, present
or represented by proxy, constitutes a quorum for the Annual
Meeting of Shareholders. Abstentions are counted as present and
entitled to vote for purposes of determining a quorum. Shares
represented by broker non-votes (see below) are also
counted as present and entitled to vote for purposes of
determining a quorum. On the Record Date,
120,872,713 shares of Aastrom common stock were outstanding
and entitled to vote.
How many
votes are required to approve each proposal?
The following explains how many votes are required to approve
each proposal, provided that a majority of our shares is present
at the Annual Meeting of Shareholders (in person or by proxy).
The three candidates for election who receive a plurality vote
in the affirmative will be elected. Ratifying
PricewaterhouseCoopers LLP as Aastroms independent
registered public accounting firm for fiscal year 2008 requires
the affirmative vote of a majority of the shares present.
How are
votes counted?
You may either vote FOR or WITHHOLD
authority to vote for each nominee for the Board of Directors.
You may vote FOR, AGAINST or
ABSTAIN on the other proposal. If you abstain from
voting on the other proposal, it has the same effect as a vote
against the proposal. If you just sign and submit your proxy
card without voting instructions, your shares will be voted
FOR each director nominee and FOR the
other proposal.
What is a
broker non-vote?
If you hold your shares in street name and do not provide voting
instructions to your broker, your shares will not be voted on
any proposal on which your broker does not have discretionary
authority to vote (a broker non-vote). Shares held by brokers
who do not have discretionary authority to vote on a particular
matter and who have not received voting instructions from their
customers are counted as present for the purpose of determining
whether there is a quorum at the Annual Meeting of Shareholders,
but are not counted or deemed to be present or represented for
the purpose of determining whether shareholders have approved
that matter.
How does
the Board recommend that I vote?
Aastroms Board recommends that you vote your shares:
|
|
|
|
|
FOR each of the nominees to the Board; and
|
|
|
|
FOR the ratification of the appointment of
PricewaterhouseCoopers LLP as Aastroms independent
registered public accounting firm for fiscal year 2008.
|
How do I
vote my shares without attending the meeting?
If you are a shareholder of record, you may vote by granting a
proxy. For shares held in street name, you may vote by
submitting voting instructions to your broker or nominee. In any
circumstance, you may vote:
|
|
|
|
|
By Internet or Telephone If you have
internet or telephone access, you may submit your proxy by
following the voting instructions on the proxy card. If you vote
by internet or telephone, you need not return your proxy card.
|
|
|
|
By Mail You may vote by mail by signing and
dating your proxy card and mailing it in the envelope provided.
You should sign your name exactly as it appears on the proxy
card. If you are signing in a representative capacity (for
example, as guardian, executor, trustee, custodian, attorney or
officer of a corporation), you should indicate your name and
title or capacity.
|
Internet and telephone voting facilities will close at
11:59 p.m., Eastern Standard Time, on November 6, 2007.
How do I
vote my shares in person at the meeting?
If you are a shareholder of record and prefer to vote your
shares at the meeting, bring the enclosed proxy card or proof of
identification. You may vote shares held in street name only if
you obtain a signed proxy from the record holder (broker or
other nominee) giving you the right to vote the shares.
Even if you plan to attend the meeting, we encourage you to vote
in advance by internet, telephone or mail so that your vote will
be counted even if you are unable to attend the meeting.
What does
it mean if I receive more than one proxy card?
It generally means you hold shares registered in more than one
account. To ensure that all your shares are voted, sign and
return each proxy card or, if you vote by internet or telephone,
vote once for each proxy card you receive.
2
May I
change my vote?
Yes. Whether you have voted by mail, internet or telephone, you
may change your vote and revoke your proxy by:
|
|
|
|
|
Sending a written statement to that effect to the Corporate
Secretary of Aastrom;
|
|
|
|
Voting by internet or telephone at a later time;
|
|
|
|
Submitting a properly signed proxy card with a later
date; or
|
|
|
|
Voting in person at the Annual Meeting of Shareholders.
|
Can I
receive future proxy materials electronically?
Yes. If you are a shareholder of record, you may elect to
receive future proxy statements and annual reports online as
described in the next paragraph. If you elect this feature, you
will receive an email message notifying you when the materials
are available, along with a web address for viewing the
materials. If you received this proxy statement electronically,
you do not need to do anything to continue receiving proxy
materials electronically in the future.
Whether you hold shares registered directly in your name, or
through a broker or bank, you can enroll for future delivery of
proxy statements and annual reports by following these easy
steps:
|
|
|
|
|
Go to our website at www.aastrom.com;
|
|
|
|
Click on Investors;
|
|
|
|
In the Shareholder Services section, click on
Shareholder Electronic Delivery; and
|
|
|
|
Follow the prompts to submit your electronic consent.
|
Generally, brokers and banks offering this choice require that
shareholders vote through the internet in order to enroll.
Street name shareholders whose broker or bank is not included in
this website are encouraged to contact their broker or bank and
ask about the availability of electronic delivery. As with all
internet usage, the user must pay all access fees and telephone
charges. You may view this years annual report and proxy
materials at www.aastrom.com/annuals.
What are
the costs and benefits of electronic delivery of Annual Meeting
of Shareholders materials?
There is no cost to you for electronic delivery. You may incur
the usual expenses associated with internet access as charged by
your internet service provider. Electronic delivery ensures
quicker delivery, allows you to print the materials at your
computer should you choose to do so, and makes it convenient to
vote your shares online. Electronic delivery also saves Aastrom
significant printing, postage and processing costs.
What are
the costs associated with the solicitation of proxies?
The cost of soliciting proxies will be borne by Aastrom. Aastrom
will solicit shareholders by mail through its regular employees,
and will request banks and brokers, and other custodians,
nominees and fiduciaries, to solicit their customers who have
stock of Aastrom registered in the names of such persons and
will reimburse them for their reasonable, out-of-pocket costs.
Aastrom may use the services of its officers, directors, and
others to solicit proxies, personally or by telephone, without
additional compensation.
3
PROPOSAL 1
ELECTION OF DIRECTORS
Aastrom has a classified Board of Directors currently consisting
of three Class I directors (George W. Dunbar, Susan L.
Wyant and Robert L. Zerbe), two Class II directors (Timothy
M. Mayleben and Stephen G. Sudovar), and two Class III
directors (Alan L. Rubino and Nelson M. Sims), who will serve
until the Annual Meetings of Shareholders to be held in 2007,
2008 and 2009, respectively, and until their respective
successors are duly elected and qualified. Directors in a class
are elected for a term of three years to succeed the directors
in such class whose terms expire at the Annual Meeting.
The nominees for election at the 2007 Annual Meeting of
Shareholders to fill the Class I positions on the Board of
Directors are George W. Dunbar, Susan L. Wyant and Robert L.
Zerbe. If elected, the nominees will serve as directors until
Aastroms Annual Meeting of Shareholders in 2010, and until
their successors are duly elected and qualified. If a nominee
declines to serve or becomes unavailable for any reason, or if a
vacancy occurs before the election, the proxies may be voted for
such substitute nominee as the proxy holders may designate. Each
person nominated for election has agreed to serve if elected and
the Board of Directors has no reason to believe that any nominee
will be unable to serve.
If a quorum is present, the three nominees for the positions as
Class I directors receiving the highest number of votes
will be elected. Abstentions and broker non-votes will have no
effect on the vote, except that abstentions and broker non-votes
will be counted as shares present for purposes of determining
the presence of a quorum. The Board of Directors unanimously
recommends a vote FOR the nominees named above.
The table below sets forth for Aastroms directors,
including the Class I nominees to be elected at this
meeting, certain information, as of August 31, 2007 with
respect to age and background.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
Name
|
|
Position With Aastrom
|
|
Age
|
|
Since
|
|
Class I directors to be elected at the 2007 Annual
Meeting of Shareholders:
|
George W. Dunbar
|
|
|
President and CEO
|
|
|
|
61
|
|
|
2006
|
Susan L. Wyant
|
|
|
Director
|
|
|
|
55
|
|
|
2002
|
Robert L. Zerbe
|
|
|
Director
|
|
|
|
56
|
|
|
2006
|
Class II directors whose terms will expire at the 2008
Annual Meeting of Shareholders:
|
Timothy M. Mayleben
|
|
|
Director
|
|
|
|
47
|
|
|
2005
|
Stephen G. Sudovar
|
|
|
Director; Chairman
|
|
|
|
61
|
|
|
2005
|
Class III directors where terms will expire at the 2009
Annual Meeting of Shareholders:
|
Alan L. Rubino
|
|
|
Director
|
|
|
|
53
|
|
|
2005
|
Nelson M. Sims
|
|
|
Director
|
|
|
|
60
|
|
|
2006
|
Nominees
for election at the 2007 Annual Meeting of
Shareholders
George W. Dunbar has served as President and Chief
Executive Officer and as a Director since July 2006. He has more
than thirty years of experience in the healthcare field,
including the biotech, pharmaceutical, diagnostic and device
sectors. During this period, he has spent more than fifteen
years as a chief executive officer of established and
early-stage healthcare companies. From 2004 through 2005, he was
the Chief Executive Officer of Quantum Dot Corporation. From
2003 through 2004 he was Chief Executive Officer of Targesome,
Inc. and also served on the Business Advisory Board of Ulteria
Capital Ltd. From 2001 through 2002, Mr. Dunbar was Chief
Executive Office of Epic Therapeutics. Prior to 2001, he served
at various times as Chief Executive Officer of Cytotherapeutics,
Stem Cells, Inc. and Metra Biosystems, and in management
positions with the Ares-Serono Group and Amersham International.
Mr. Dunbar received a B.S. in Electrical Engineering and an
MBA from Auburn University. Mr. Dunbar currently serves on
the board of directors of Sonus Pharmaceuticals as well as on
the MBA Advisory Board of the Auburn University College of
Business.
Susan L. Wyant, Pharm.D, a Director since June 2002, is
the founder and President of The Dominion Group, a full service
marketing research and consulting firm assisting major
pharmaceutical as well as
start-up
4
biotechnology companies in making informed business decisions.
Prior to founding The Dominion Group in 1993, Dr. Wyant
held various marketing and management positions related to the
pharmaceutical industry. In addition to her extensive work in
pharmaceutical consulting and marketing, Dr. Wyant has been
a Clinical Associate Professor at Medical College of Virginia
School of Pharmacy and Shenandoah University School of Pharmacy.
Dr. Wyant received a Bachelor of Science degree and a
Doctor of Pharmacy degree from the Medical College of
Virgina/VCU School of Pharmacy.
Robert L. Zerbe, M.D., a Director since January
2006, is the Chief Executive Officer of QUATRx Pharmaceuticals
Company a venture-backed drug development company which he
co-founded in 2000. Prior to this, Dr. Zerbe held several
senior executive management positions with major pharmaceutical
companies including Eli Lilly and Pfizer (formerly Parke-Davis).
During his tenure at Eli Lilly, Dr. Zerbes clinical
research and development positions included Managing Director,
Lilly Research Center U.K., and Vice President of Clinical
Investigation and Regulatory Affairs. He joined Pfizer in 1993,
becoming Senior Vice President of Worldwide Clinical Research
and Development. In this capacity he led the clinical
development programs for a number of key products, including
Lipitor®
and
Neurontin®.
Dr. Zerbe received his M.D. from the Indiana University
School of Medicine, and has completed post-doctoral work in
internal medicine, endocrinology and neuroendocrinology at
Indiana University and the National Institutes of Health. He
also serves on the boards of A.P. Pharma, Inc. and Anesiva, Inc.
Directors
Continuing In Office
Timothy M. Mayleben, a Director since June 2005, is the
President and Chief Operating Officer and a Director of
NightHawk Radiology Holdings, Inc., the leading provider of
radiology services to radiology groups across the
U.S. Prior to this he was an advisor to life science and
healthcare companies through his advisory and investment firm,
ElMa Advisors. Mr. Mayleben was formerly the Chief
Operating Officer of Esperion Therapeutics, which later became a
division of Pfizer Global Research & Development. He
joined Esperion in late 1998 as Chief Financial Officer. While
at Esperion, Mr. Mayleben led the raising of more than
$200 million in venture capital and institutional equity
funding and later negotiated the acquisition of Esperion by
Pfizer in December 2003. Prior to joining Esperion,
Mr. Mayleben held various senior and executive management
positions at Transom Technologies, Inc., now part of Electronic
Data Systems, Inc., and Applied Intelligent Systems, Inc., which
was acquired by Electro-Scientific Industries, Inc. in 1997.
Mr. Mayleben holds a Masters of Business Administration
with distinction from the J.L. Kellogg Graduate School of
Management at Northwestern University, and a Bachelor of
Business Administration degree from the University of Michigan
Ross Business School. He is on the Advisory Board for the
Wolverine Venture Fund.
Alan L. Rubino, a Director since September 2005, is the
President and Chief Operating Officer of Pharmos Corporation, a
public specialty pharmaceutical firm with corporate headquarters
based in Iselin, NJ. Mr. Rubino has continued to expand
upon a career that included Hoffmann-LaRoche, Inc. from 1977 to
2001, where he was a member of the U.S. Executive and
Operating Committees and an SEC corporate officer. During his
Roche tenure, he held a series of key executive positions in
marketing, sales, business operations, supply chain and human
resource management. In addition, he was assigned to various
executive committee roles in the areas of marketing, project
management, and globalization of Roche Holdings. Mr. Rubino
also held senior executive positions at PDI, Inc. and Cardinal
Health from 2001 to 2005. He received Bachelor of Arts degree in
economics from Rutgers University with a minor in
biology/chemistry, and completed post-graduate educational
programs at the University of Lausanne and Harvard Business
School. Additionally, he serves on the Board of Rutgers
University Business School.
Nelson M. Sims, a Director since February 2006, has over
30 years of experience in senior management of companies in
the pharmaceutical industry. From 2003 through 2005, he served
as President of Novavax, Inc., a specialty biopharmaceutical
company. From 1984 through 2001, he served in various management
positions in the sales, marketing and business development areas
of Eli Lilly and Company, including Executive Director of
Alliance Management, President of Eli Lilly Canada, and Vice
President, Sales and Marketing at Hybritech. Mr. Sims
received a Bachelor of Science degree in Pharmacy from
Southwestern Oklahoma State University and completed the Tuck
Executive Program at the Amos Tuck School of Business at
Dartmouth College. He serves on the board of directors of MDS,
Inc. and ATS, Inc., and has previously served on the boards of
several life science companies and community service
organizations.
5
Stephen G. Sudovar, Chairman since November 2006 and a
Director since July 2005, is currently the CEO of SGS
Associates, a healthcare management consulting firm. Before
this, Mr. Sudovar served as President and CEO of EluSys
Therapeutics, Inc., a
start-up
biopharmaceutical company with a pipeline of products in various
stages of development. Prior to joining EluSys in 1999,
Mr. Sudovar was the President of Roche Laboratories, Inc.,
a division of Hoffmann LaRoche, Inc. Before he assumed the
duties of President at Roche, Mr. Sudovar held the
positions of Senior Vice President, Executive Director of
Special Projects at Basel Headquarters (Switzerland), and Vice
President and General Manager. Prior to joining Roche,
Mr. Sudovar was the CEO and Chairman of Pracon
Incorporated, a health care consulting and communications firm
he founded and presided over for ten years. Mr. Sudovar
holds a Bachelor of Science degree in Marketing and Finance from
St. Peters College, and a Masters of Business
Administration degree from Fairleigh Dickinson University.
Board
Meetings and Committees
During the fiscal year ended June 30, 2007, the Board of
Directors held five meetings. Each director serving on the Board
of Directors in fiscal year 2007 attended at least 75% of such
meetings of the Board of Directors and the Committees on which
he or she served.
The Audit Committees function is to review with
Aastroms independent accountants and management the annual
financial statements and independent accountants opinion,
review the scope and results of the examination of
Aastroms financial statements by the independent
accountants, review all professional services performed and
related fees by the independent accountants, approve the
retention of the independent accountants and periodically review
Aastroms accounting policies and internal accounting and
financial controls. The members of the Audit Committee for the
fiscal year 2007 were Timothy M. Mayleben, Alan L. Rubino and
Nelson M. Sims. Stephen G. Sudovar was a member of the
Audit Committee until he was appointed Chairman in November
2006. During the fiscal year ended June 30, 2007, the Audit
Committee held four meetings. All members of the Companys
Audit Committee are independent (as independence is defined in
Rule 4200(a)(15) of the NASD listing standards).
Mr. Mayleben has been designated as an audit committee
financial expert, as defined in the rules of the Securities and
Exchange Commission (the SEC). The Audit Committee
acts pursuant to a written charter, which is available at the
Companys website, www.aastrom.com. For additional
information concerning the Audit Committee, see Report of
the Audit Committee of the Board of Directors.
The Compensation Committees function is to review and
recommend to the full board salary and bonus levels and stock
option or restricted stock grants with respect to executive
officers, and to review and approve stock option or restricted
stock grants with respect to all employees. The members of the
Compensation Committee for the entire fiscal year 2007 were
Timothy M. Mayleben and Alan L. Rubino. Susan L. Wyant
joined the Compensation Committee in Novemeber 2006 when Stephen
G. Sudovar left the committee upon his appointment as Chairman.
During the fiscal year ended June 30, 2007, the
Compensation Committee held seven meetings. All members of the
Companys Compensation Committee are independent (as
independence is defined in Rule 4200(a)(15) of the NASD
listing standards). The Compensation Committee acts pursuant to
a written charter, which is available at the Companys
website, www.aastrom.com. For additional information
concerning the Compensation Committee, see Report of the
Compensation Committee of the Board of Directors on Executive
Compensation and Executive Compensation and Other
Matters.
The Corporate Governance and Nominating Committees (the
Governance Committee) function is to assist
Aastroms Board of Directors in fulfilling its
responsibilities by reviewing and reporting to the Board of
Directors upon (i) corporate governance compliance
mechanisms, (ii) corporate governance roles amongst
management and directors, and (iii) Board of Directors
process enhancement. This committee also considers qualified
candidates for appointment and nomination for election to the
Board of Directors and makes recommendations concerning such
candidates. Consistent with this function, the Governance
Committee encourages continuous improvement of, and fosters
adherence to, the Companys corporate governance policies,
procedures and practices at all levels. The members of the
Governance Committee for the fiscal year 2007 were Nelson M.
Sims, Susan L. Wyant and Robert L. Zerbe. Stephen G.
Sudovar was a member of the Governance Committee until he was
appointed Chairman in November 2006. During the fiscal year
ended June 30, 2007, the Governance Committee held four
meetings. All the members of the Governance Committee are
independent (as independence is defined in Rule 4200(a)(15)
of the NASD listing standards). The Governance Committee acts
pursuant to a written charter
6
which is available at the Companys website,
www.aastrom.com. For additional information concerning
the Governance Committee, see Report of the Corporate
Governance and Nominating Committee of the Board of
Directors.
Director
Nominations
The Governance Committee evaluates and recommends to the Board
of Directors the nominees for each election of directors. In
fulfilling its responsibilities, the Governance Committee
considers the following factors:
|
|
|
|
|
the appropriate size of the Companys Board and its
committees
|
|
|
|
the needs of the Company with respect to the particular talents
and experience of its directors
|
|
|
|
the nominees interest in becoming an effective,
collaborative Board member, and the nominees ability to
work in a collegial style with other Board members
|
|
|
|
the knowledge, skills and experience of nominees, including
experience in the life sciences industry, medical products,
medical research, medicine, business, finance, administration or
public service
|
|
|
|
experience with accounting rules and practices
|
|
|
|
experience with applicable regulatory and SEC requirements
applicable to public companies
|
|
|
|
experience with regulatory requirements applicable to the
Companys industry
|
|
|
|
appreciation of the relationship of the Companys business
to the changing needs of society
|
|
|
|
balance between the benefit of continuity and the desire for a
fresh perspective provided by new members
|
The Governance Committees goal is to assemble a Board that
brings to the Company a variety of perspectives and skills
derived from high quality business and professional experience.
In doing so, the Governance Committee also considers candidates
with appropriate non-business backgrounds.
Other than the foregoing, there are no stated minimum criteria
for director nominees. However, the Governance Committee may
also consider such other factors as it may deem are in the best
interests of the Company and its shareholders. The Governance
Committee does, however, recognize that under applicable
regulatory requirements at least one member of the Board must,
and believes that it is preferable that more than one member of
the Board should, meet the criteria for an audit committee
financial expert as defined by SEC rules, and that at
least a majority of the members of the Board must meet the
definition of independent director under NASD
listing standards or the listing standards of any other
applicable self regulatory organization. The Governance
Committee also believes it appropriate for at least one member
of the Companys management to participate as a member of
the Board.
The Governance Committee identifies nominees by first evaluating
the current members of the Board willing to continue in service.
Current members of the Board with skills and experience that are
relevant to the Companys business and who are willing to
continue in service are considered for re-nomination, balancing
the value of continuity of service by existing members of the
Board with that of obtaining a new perspective. If any member of
the Board up for re-election at an upcoming annual meeting of
shareholders does not wish to continue in service, the
Governance Committee identifies the desired skills and
experience of a new nominee in light of the criteria above.
Current members of the Governance Committee and Board will be
polled for suggestions as to individuals meeting the criteria of
the Governance Committee. Research may also be performed to
identify qualified individuals. If the Governance Committee
believes that the Board requires additional candidates for
nomination, the Governance Committee may explore alternative
sources for identifying additional candidates. This may include
engaging, as appropriate, a third party search firm to assist in
identifying qualified candidates.
The Governance Committee will evaluate any recommendation for
director nominee proposed by a shareholder who (i) has
continuously held at least 1% of the outstanding shares of the
Companys common stock entitled to vote at the annual
meeting of shareholders for at least one year by the date the
shareholder makes the recommendation and (ii) undertakes to
continue to hold the common stock through the date of the
meeting. In order to be evaluated in connection with the
Companys established procedures for evaluating potential
director
7
nominees, any recommendation for director nominee submitted by a
qualifying shareholder must be received by the Company no later
than 120 days prior to the anniversary of the date proxy
statements were mailed to shareholders in connection with the
prior years annual meeting of shareholders. Any
shareholder recommendation for director nominee must be
submitted to the Corporate Secretary, in writing at 24 Frank
Lloyd Wright Drive, Lobby K, Ann Arbor, Michigan 48105 and must
contain the following information:
|
|
|
|
|
a statement by the shareholder that
he/she is
the holder of at least 1% of the Companys common stock and
that the stock has been held for at least a year prior to the
date of the submission and that the shareholder will continue to
hold the shares through the date of the annual meeting of
shareholders
|
|
|
|
the candidates name, age, contact information and current
principal occupation or employment
|
|
|
|
a description of the candidates qualifications and
business experience during, at a minimum, the last five years,
including
his/her
principal occupation and employment and the name and principal
business of any corporation or other organization in which the
candidate was employed
|
|
|
|
the candidates resume
|
The Governance Committee will evaluate recommendations for
director nominees submitted by directors, management or
qualifying shareholders in the same manner, using the criteria
stated above.
All directors and director nominees will submit a completed form
of directors and officers questionnaire as part of
the nominating process. The process may also include interviews
and additional background and reference checks for non-incumbent
nominees, at the discretion of the Governance Committee.
Shareholder
Communications with Directors
The Board has adopted a Shareholder Communications with
Directors Policy. The Shareholder Communications with Directors
Policy is available on the Companys website,
www.aastrom.com.
Director
Attendance at Annual Meetings
The Board has adopted a Director Attendance at Annual Meetings
Policy. This policy is available on the Companys website,
www.aastrom.com. All of the directors then in office,
with the exception of R. Douglas Armstrong, attended the Annual
Meeting of Shareholders held in November 2006.
Code of
Ethics
The Board has adopted a Code of Ethics that applies to all of
our employees, officers and directors. The Code of Ethics is
available at the Companys website, www.aastrom.com.
Board
Member Independence
The Board has determined that all of the Board members except
for Mr. Dunbar are independent as independence
is defined in Rule 4200(a)(15) of the NASD listing
standards. Mr. Dunbar is not considered independent because
of his current employment by the Company.
8
PROPOSAL 2
RATIFICATION OF APPOINTMENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has selected PricewaterhouseCoopers LLP as
independent public accountants to audit the consolidated
financial statements of Aastrom for the fiscal year ending
June 30, 2008. PricewaterhouseCoopers LLP has acted in such
capacity since its appointment in fiscal year 1997. A
representative of PricewaterhouseCoopers LLP is expected to be
present at the Annual Meeting, with the opportunity to make a
statement if the representative desires to do so, and is
expected to be available to respond to appropriate questions.
Shareholder ratification of the selection of
PricewaterhouseCoopers LLP as the Companys independent
auditors is not required by the Companys Bylaws or
otherwise. However, the Board is submitting the selection of
PricewaterhouseCoopers LLP to the shareholders for ratification
as a matter of good corporate practice. If the shareholders fail
to ratify the selection, the Audit Committee will reconsider
whether or not to retain that firm. Even if the selection is
ratified, the Audit Committee in its discretion may direct the
appointment of different independent auditors at any time during
the year if they determine that such a change would be in the
best interests of the Company and its shareholders.
As part of its duties, the Audit Committee considers whether the
provision of services, other than audit services, during the
fiscal year ended June 30, 2007 by PricewaterhouseCoopers
LLP, the Companys independent auditor for that period, is
compatible with maintaining the auditors independence. The
following table sets forth the aggregate fees billed to the
Company for the fiscal years ended June 30, 2007 and
June 30, 2006 by PricewaterhouseCoopers LLP:
|
|
|
|
|
|
|
|
|
|
|
June 30, 2007
|
|
|
June 30, 2006
|
|
|
Audit Fees
|
|
$
|
347,847
|
(1)
|
|
$
|
336,197
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The Audit Fees for the year ended June 30, 2007, were for
professional services rendered for the audits and reviews of the
consolidated financial statements of the Company, professional
services rendered for a federal compliance audit, issuance of
consents and assistance with review of documents filed with the
SEC. |
|
(2) |
|
The Audit Fees for the year ended June 30, 2006, were for
professional services rendered for the audits and reviews of the
consolidated financial statements of the Company, professional
services rendered for a federal compliance audit, issuance of
consents and assistance with review of documents filed with the
SEC and statutory audits. |
The Audit Committee approves in advance the engagement and fees
of the independent public accountants for all audit services and
non-audit services, based upon independence, qualifications and,
if applicable, performance. The Audit Committee may form and
delegate to subcommittees of one or more members of the Audit
Committee the authority to grant pre-approvals for audit and
permitted non-audit services, up to specific amounts. All Audit
Committee services provided by PricewaterhouseCoopers LLP for
the fiscal year 2007 were pre-approved by the Audit Committee.
Vote
Required and Board of Directors Recommendation
The affirmative vote of a majority of the votes cast on the
ratification of this appointment, at the Annual Meeting of
shareholders at which a quorum representing a majority of all
outstanding shares of common stock of Aastrom is present, either
in person or by proxy, is required for ratification of this
proposal. Abstentions and broker non-votes will each be counted
as present for purposes of determining the presence of a quorum
but will not have any effect on the outcome of the proposal.
The Board of Directors unanimously recommends a vote
FOR the ratification of the appointment of
PricewaterhouseCoopers LLP as Aastroms Independent
Registered Public Accounting Firm for the Fiscal Year Ending
June 30, 2008.
9
STOCK
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information, as of
August 31, 2007 with respect to the beneficial ownership of
Aastroms common stock by (i) all persons known by
Aastrom to be the beneficial owners of more than 5% of the
outstanding common stock of Aastrom; (ii) each director of
Aastrom, (iii) each executive officer of Aastrom named in
the Summary Compensation Table, and (iv) all executive
officers and directors of Aastrom as a group.
|
|
|
|
|
|
|
|
|
|
|
Shares Owned(1)
|
|
|
|
|
|
|
Percentage of
|
|
Name and Address of Beneficial Owner(2)
|
|
Number of Shares
|
|
|
Class(3)
|
|
|
George W. Dunbar(4)
|
|
|
635,000
|
|
|
|
*
|
|
Gerald D. Brennan(5)
|
|
|
124,900
|
|
|
|
*
|
|
Elmar R. Burchardt(6)
|
|
|
62,500
|
|
|
|
*
|
|
Robert J. Bard(7)
|
|
|
132,150
|
|
|
|
*
|
|
R. Douglas Armstrong(8)
|
|
|
1,957,448
|
|
|
|
1.6
|
%
|
Timothy M. Mayleben(9)
|
|
|
70,150
|
|
|
|
*
|
|
Alan L. Rubino(10)
|
|
|
70,150
|
|
|
|
*
|
|
Nelson M. Sims(11)
|
|
|
49,250
|
|
|
|
*
|
|
Stephen G. Sudovar(12)
|
|
|
80,150
|
|
|
|
*
|
|
Susan L. Wyant(13)
|
|
|
100,150
|
|
|
|
*
|
|
Robert L. Zerbe(14)
|
|
|
54,583
|
|
|
|
*
|
|
All officers and directors as a group (8 persons)(15)
|
|
|
1,246,833
|
|
|
|
*
|
|
|
|
|
* |
|
Represents less than 1% of the outstanding shares of
Aastroms common stock. |
|
(1) |
|
Except as indicated in the footnotes to this table, the persons
named in the table have sole voting and investment power with
respect to all shares of common stock shown as beneficially
owned by them, subject to community property laws, where
applicable. The number of shares owned and percentage ownership
amounts include shares of restricted stock granted under
Aastroms 2004 Equity Incentive Plan. |
|
(2) |
|
Unless otherwise provided, the address for each beneficial owner
is 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48105. |
|
(3) |
|
Calculated on the basis of 120,874,063 shares of common
stock outstanding as of August 31, 2007 except the shares
of common stock underlying options exercisable within
60 days of August 31, 2007 are deemed to be
outstanding for purposes of calculating ownership of securities
of the holders of such options. |
|
(4) |
|
Includes 625,000 shares issuable upon exercise of options
held by Mr. Dunbar that are exercisable within the
60-day
period following August 31, 2007. |
|
(5) |
|
Includes 114,900 shares issuable upon exercise of options
held by Mr. Brennan that are exercisable within the
60-day
period following August 31, 2007. |
|
(6) |
|
Includes 62,500 shares issuable upon exercise of options
held by Dr. Burchardt that are exercisable within the
60-day
period following August 31, 2007. |
|
(7) |
|
Includes 122,100 shares issuable upon exercise of options
held by Mr. Bard that are exercisable within the
60-day
period following August 31, 2007. |
|
(8) |
|
Includes 1,349,875 shares issuable upon exercise of options
held by Dr. Armstrong that are exercisable within the
60-day
period following August 31, 2007. Also, includes
68,000 shares held in trusts in which Dr. Armstrong is
a co-trustee; Dr. Armstrong disclaims beneficial ownership
of all such shares except to the extent of his pecuniary
interest therein. |
|
(9) |
|
Includes 63,250 shares issuable upon exercise of options
held by Mr. Mayleben that are exercisable within the
60-day
period following August 31, 2007. |
10
|
|
|
(10) |
|
Includes 63,250 shares issuable upon exercise of options
held by Mr. Rubino that are exercisable within the
60-day
period following August 31, 2007. |
|
(11) |
|
Includes 43,750 shares issuable upon execution of options
held by Mr. Sims that are exercisable within the
60-day
period following August 31, 2007. |
|
(12) |
|
Includes 63,250 shares issuable upon exercise of options
held by Mr. Sudovar that are exercisable within the
60-day
period following August 31, 2007. |
|
(13) |
|
Includes 93,250 shares issuable upon exercise of options
held by Dr. Wyant that are exercisable within the
60-day
period following August 31, 2007. |
|
(14) |
|
Includes 47,383 shares issuable upon execution of options
held by Dr. Zerbe are exercisable within the
60-day
period following August 31, 2007. |
|
(15) |
|
Includes 1,176,533 shares issuable upon exercise of options
that are exercisable within the
60-day
period following August 31, 2007. |
11
EXECUTIVE
COMPENSATION AND RELATED INFORMATION
Compensation
Discussion and Analysis
Overview
of Compensation Program and Philosophy
Aastroms compensation program is intended to meet three
principal objectives: (1) attract, reward and retain
officers and other key employees; (2) motivate these
individuals to achieve short-term and long-term corporate goals
that enhance shareholder value; and (3) support
Aastroms core values and culture, by promoting internal
equity and external competitiveness. To meet these objectives,
Aastrom has adopted the following compensation guidelines:
|
|
|
|
|
Pay compensation that is competitive with the practices of other
similarly situated biotechnology companies; and
|
|
|
|
Pay for performance by:
|
|
|
|
|
|
setting challenging performance goals for our officers and
providing a short-term incentive through an incentive
compensation plan that is based upon achievement of these
goals; and
|
|
|
|
providing long-term, significant incentives in the form of stock
options, in order to retain those individuals with the
leadership abilities necessary for increasing long-term
shareholder value while aligning the interests of our officers
with those of our shareholders.
|
The above policies guide the Compensation Committee (the
Committee) in assessing the proper allocation
between long-term compensation, current cash compensation and
short-term incentive compensation. Other considerations include
Aastroms business objectives, its fiduciary and corporate
responsibilities (including internal equity considerations and
affordability), competitive practices and trends and regulatory
requirements.
In determining the particular elements of compensation that will
be used to implement Aastroms overall compensation
policies, the Committee takes into consideration a number of
factors related to Aastroms performance, such as
Aastroms clinical trial progress and and
business-unit-specific
operational and financial performance, as well as competitive
practices among our peer group.
Aastroms executive compensation program is overseen and
administered by the Committee, which is comprised entirely of
independent directors, as determined in accordance with
applicable Nasdaq, SEC and Internal Revenue Code
(IRC) rules.
Role
of Compensation Consultant in Advising the
Committee
The Committee has the authority to engage its own independent
advisors to assist in carrying out its responsibilities and has
done so. During 2007, the Committee retained an independent
compensation consulting firm, F.W. Cook and Associates
(F.W. Cook), to assist in reviewing and
recommending certain Aastrom compensation policies.
F.W. Cook advised the Committee on certain aspects of executive
and director compensation, including base salaries and annual
and long-term stock option grants, participated in several
meetings of the Committee and also communicated with the
Committee outside of meetings. F.W. Cook reports to the
Committee rather than to management, although they met with
management for purposes of gathering information on proposals
that management made to the Committee. The Committee is free to
replace F.W. Cook or hire additional consultants at any time.
F.W. Cook does not provide any other services to Aastrom and
receives compensation only with respect to the services provided
to the Committee.
Role
of Management in Setting Compensation
The Committee on occasion meets with Aastroms President
and Chief Executive Officer, Mr. Dunbar,
and/or other
executives to obtain feedback and recommendations with respect
to Company compensation programs, practices and packages for
executives, other employees and directors. Management makes
recommendations to the Committee on the base salary, cash
incentive targets and equity compensation for the executive team
and other
12
employees. The Committee considers, but is not bound by and does
not always accept, managements recommendations with
respect to executive compensation. The Committee has
significantly changed several of managements compensation
proposals in recent years, including fiscal year 2007. The
Committee also typically seeks input from an independent
compensation consultant prior to making any final determinations.
Mr. Dunbar and Mr. Brennan attend some of the
Committees meetings, but the Committee also holds
executive sessions not attended by any members of management or
non-independent directors. The Committee discusses
Mr. Dunbars compensation package with him, but makes
decisions with respect to Mr. Dunbars compensation
without him present. The Committee has the authority to make
recommendations to the full board with respect to the
compensation of our named executive officers. The Committee has
authorized Mr. Dunbar to make salary adjustments and
short-term cash incentive (bonus) decisions for all employees
other than the named executive officers and
Mr. Dunbars other direct reports. The Committee has
not delegated any of its authority with respect to the
compensation of named executive officers.
Elements
of Compensation
There are six major elements that comprise Aastroms
compensation program: (i) base salary; (ii) annual
incentive opportunities, including bonuses; (iii) stock
option awards at hiring; (iv) annual stock option awards;
(v) retirement benefits provided under a 401(k) plan; and
(vi) executive perquisites and other benefit programs
generally available to all employees. Aastrom has selected these
elements because each is considered useful
and/or
necessary to meet one or more of the principal objectives of our
compensation policy. For instance, base salary and bonus target
percentages are set within a framework of industry competitive
norms and adequately compensating and rewarding employees on a
day-to-day basis for the services they perform, while our equity
programs are geared toward providing an incentive and reward for
the achievement of long-term business objectives and retaining
key talent. Aastrom believes that these elements of
compensation, when combined, are effective, and will continue to
be effective, in achieving the objectives of our compensation
program.
The Committee reviews the compensation program on an annual
basis, including each of the above elements, to ensure that
benefit levels remain competitive. In setting compensation
levels for a particular executive, the Committee takes into
consideration the compensation package as a whole, and each
element individually, and the executives past and expected
future contributions to our business. Aastrom has employment and
severance agreements with each of our executive officers. These
employment and severance agreements are discussed below in the
section entitled Employment Contracts and Termination of
Employment and Change of Control Arrangements.
Base
Salary and Annual Incentive Opportunities
Aastrom makes base salaries and incentive bonuses a significant
portion of the executive compensation package in order to remain
competitive in attracting and retaining executive talent. Annual
incentive bonuses are paid in recognition of the achievement of
our business goals. The Committee determines each officers
target total annual cash compensation (salary and bonuses) after
reviewing comparable compensation information from a group of
similarly sized biotechnology companies. For fiscal year 2007,
this review occurred in July through September and in prior
years has occurred at other times as determined by the
Committee. The peer group was selected based on data from the
Radford Survey for similarly sized biotechnology companies with
whom Aastrom may compete for executive talent for fiscal year
2007. The Committee currently intends to continue using, subject
to modification, a similar survey and group of companies for
fiscal 2008.
Data on the compensation practices of the Radford Survey is
generally compiled by the Radford organization and published as
a fee based service. Peer group data is also gathered with
respect to all equity awards (including stock options,
restricted stock and restricted stock units) through F. W. Cook.
Neither source of data includes generally available benefits,
such as 401(k) plans or health care coverage.
Aastroms goal is to, over time, target base pay and total
cash compensation near the median level among its peer group.
However, in determining base salary, the Committee also
considers other factors such as job performance, skill set,
prior experience, the executives time in his position
and/or with
Aastrom, internal consistency regarding pay levels for similar
positions or skill levels within the Company, external pressures
to
13
attract and retain talent, and market conditions generally. Base
pay and target cash compensation are analyzed by management to
determine variances to our compensation targets using the
combination of publicly available information and survey data as
described above. Mr. Dunbar uses the market data in making
his recommendations to the Committee for his direct reports.
Effective in September 2006, after taking into consideration the
above compensation targets and Mr. Dunbars
recommendations, the Committee increased the base salaries of
each of the named executive officers except: for:
(i) Mr. Dunbar, whose salary was deemed to be at
market as a result of his recent hiring that occurred in July
2006 and (ii) Dr. Armstrong who terminated his
employment with the Company in July 2006.
Payment of bonus amounts, and therefore total cash compensation,
depends on the achievement of specified performance goals. For
fiscal year 2007, Mr. Dunbar made recommendations to the
Committee with respect to target bonus amounts, expressed as a
percentage of base salary, for each of the named executive
officers other than Dr. Armstrong and himself. These recommended
bonus amounts were consistent with our intention to target total
cash compensation based on a number of factors including: the
median level of peer companies, individual performance,
experience in the position, skill level and the Companys
performance. Generally none of the named executive officers had
total cash compensation targeted above the median level of the
peer group of companies as determined in the Radford survey. The
cash bonuses for fiscal year 2007 are discussed below.
Executive
Incentive Bonus Plan
Aastrom maintains an annual incentive bonus program for senior
executives to encourage and award achievement of Aastroms
business goals and to assist Aastrom in attracting and retaining
executives by offering an opportunity to earn a competitive
level of compensation. Based on these and the objectives
described above, the Committee developed and approved specific
performance targets for use during fiscal year 2007 under the
Aastrom Biosciences Inc. Amended Employee Compensation
Guidelines (Compensation Plan), in which our named
executive officers listed in the 2007 Summary Compensation Table
participated during fiscal year 2007. The Compensation Plan
covers both cash and equity related compensation paid to
officers.
Incentive bonuses are paid under the Compensation Plan only if
the performance goals that the Committee sets at or near the
beginning of the fiscal year are achieved. The Committee
establishes a bonus formula that is applied to the achieved
performance. The bonus formula is based on the anticipated
difficulty and relative importance of achieving the performance
goals. Accordingly, the bonuses paid, if any, for any given
fiscal year will vary depending on actual performance. To help
achieve Aastroms goal of retaining key talent, an
executive must remain an employee for the entire fiscal year
2007 year in order to be eligible for any bonus under the
Compensation Plan that relates to fiscal year 2007. The
Committee has the discretion to increase or decrease bonuses
under the Compensation Plan, but Mr. Dunbars final
bonus is confirmed by the full board.
Historically, bonuses have been payable in cash.
The Committee can choose a range of performance measures as
specified in the Compensation Plan. Bonuses paid under the
Compensation Plan are designed to reward progress toward and
achievement of the performance goals. For fiscal year 2007, the
Committee determined that it would be appropriate to choose the
same performance measures for all executives. For fiscal year
2007, the Committee chose measures related to (1) clinical
trial progress, (2) research objectives and
(3) certain other management objectives which included,
among other things, manufacturing infrastructure, marketing
development and facilities
In addition, the payment of the bonus requires the Company to
meet certain financial objectives.
The potential bonus for which Mr. Dunbar was eligible under
the Compensation Plan for fiscal year 2007 ranged from zero to a
maximum of 40% of his annual base salary. The potential bonus
for each of the other named executive officers under the
Compensation Plan (who continued to be employed by the Company
after July of 2006) ranged from zero to a maximum of 30% of
the individuals annual base salary. As noted above, total
cash compensation is determined considering the
50th percentile
of peer companies as well individual performance, experience in
the position, skill level of the individual and the
Companys performance. Generally none of the named
executives has total cash compensation targeted above the
50th percentile
of the peer group of companies as determined in the Radford
survey.
14
Following the end of fiscal year 2006, the Committee compared
Aastroms actual performance to the targeted performance
for the year as specified by the Committee in early fiscal year
2006, and applied the fiscal year 2006 bonus formula under the
Compensation Plan to this actual performance. In fiscal year
2006, Aastrom did not achieve all of the management objectives
specified by the Committee in early fiscal year 2006. Applying
the pre-established bonus formula to the financial performance
and management objectives we achieved, resulted in bonuses that
were paid at approximately 80% of target levels. Bonuses paid to
our named executive officers under the Compensation Plan for
fiscal year 2006 were:
|
|
|
|
|
|
|
Amount
|
|
|
George W. Dunbar
|
|
$
|
|
|
Gerald D. Brennan
|
|
$
|
45,900
|
|
Elmar R. Burchardt
|
|
$
|
10,750
|
|
Robert J. Bard
|
|
$
|
49,128
|
|
R. Douglas Armstrong
|
|
$
|
88,320
|
|
In November 2006, the Committee set the bonus formula and
performance goals that will be used to determine bonuses, if
any, under the Compensation Plan for fiscal year 2007. Whether
any bonuses will be paid depends on actual performance during
fiscal year 2007 in comparison to the goals specified by the
Committee. The fiscal year 2007 target bonus formula and
percentages for the named executive officers are the same as
those used in fiscal year 2006. The performance measures
include, among other things, clinical trial progress, research
progress, manufacturing and certain operational and financial
goals.
Long-Term
Incentive Compensation
Aastrom provides long-term incentive compensation through awards
of stock options that generally vest over multiple years. In
previous years we also used restricted stock grants that were
also subject to vesting. Aastroms equity compensation
program is intended to align the interests of our officers with
those of our shareholders by creating an incentive for our
officers to maximize shareholder value. The equity compensation
program is also designed to encourage our officers to remain
employed with Aastrom despite a very competitive labor market.
Aastrom targets the value of its equity awards to be in the
50th
percentile of the peer group mentioned above, based on the
information gathered from publicly available sources and the
Committees consultant.
Equity-based incentives are granted to our officers under
Aastroms shareholder-approved 2004 Equity Incentive Plan
(the 2004 Plan). All stock option grants have a per
share exercise price equal to the fair market value of
Aastroms common stock on the grant date. The Committee has
not granted, nor does it intend in the future to grant, equity
compensation awards to executives in anticipation of the release
of material nonpublic information that is likely to result in
changes to the price of Aastrom common stock, such as a
significant positive or negative earnings announcement.
Similarly, the Committee has not timed, nor does it intend in
the future to time, the release of material nonpublic
information based on equity award grant dates. Also, because
equity compensation awards typically vest over a four-year
period, the value to recipients of any immediate increase in the
price of Aastroms stock following a grant will be
minimized. In fiscal year 2007 the Committee began the practice
of holding monthly meetings to make initial grants to new
employees including potentially new Executive Officers effective
on the later of their hire date or the Committees meeting
date at which the grant was made.
The Committee regularly monitors the biotechnology industry in
which Aastrom operates and makes changes to our equity
compensation program to help us meet our goals, including
achieving long-term shareholder value. In order to continue to
attract and retain highly skilled employees, the Committee,
based in part on recommendations from F.W. Cook, a consulting
firm engaged by the Committee, approved changes to
Aastroms equity compensation program for fiscal year 2007
that were designed to incentivize Aastroms employees for
their hard work and commitment to the long-term success and
growth of Aastrom. In November 2006 and August 2007, the
Committee granted performance options to Mr. Brennan and
certain non-executive employees. Mr. Brennan received
grants of 280,400 and 69,400. Mr. Dunbar received a grant
of 500,000 options at his hire date subject to the same
performance targets. Aastrom granted stock options because they
can be an effective tool for meeting Aastroms compensation
goal of increasing long-term shareholder value by tying the
value of the stock options to Aastroms performance in the
future. Employees are able to profit from stock options only if
Aastroms stock price increases in value over the
15
stock options exercise price. Aastrom believes the options
that were granted provide effective incentives to option holders
to achieve increases in the value of Aastroms stock. In
fiscal year 2006, Aastrom began granting restricted stock to
employees because using restricted stock provided a more
predictable value to employees than stock options, and therefore
are efficient tools in retaining and motivating employees, while
also serving as an incentive to increase the value of
Aastroms stock. This practice was discontinued in fiscal
year 2007 on the recommendation of the Committeees
consultant after considering the Companys stage of
development and the alternative incentive tools available.
In September 2006, the Committee relied upon the above-mentioned
factors to approve stock option awards for the named executive
officers and for other employees (a few non-executive employees
elected to receive restricted stock on a transition plan from
the prior program). Management made recommendations to the
Committee with respect to equity award grants based on
guidelines that include award ranges for employees at specific
job responsibility levels and performance ratings. The fiscal
year 2007 stock option awards for all employees vest 25% on the
first anniversary of the grant date and 6.25% for each of the
next twelve quarters and typically have a ten-year term.
Restricted stock awards vest 25% annually on the anniversary of
the award date.
Retirement
Benefits Under the 401(k) Plan, Executive Perquisites and
Generally Available Benefits
The Aastrom Employees Retirement Plan, a tax qualified
401(k) plan (the 401(k) Plan), was implemented on
January 1, 1994. The majority of Aastroms employees,
including the named executive officers, who are at least
21 years of age and complete one quarter of service, are
eligible to enroll in the 401(k) Plan. The participant may
contribute a percentage of his or her annual compensation
subject to maximum annual contribution limitations. Aastrom may
match participant contributions up to 5% of annual employee
compensation not to exceed specified annual limits. The amounts
contributed by Aastrom are 100% vested after three years of
service. Generally, the maximum annual amount that any
participant could contribute in 2007 was $15,500 and the maximum
employer matching contribution based on the 2007 Internal
Revenue Code compensation limitation of $225,000 was $11,250.
In fiscal year 2007, the named executive officers were eligible
to receive health care insurance coverage and additional
benefits that are generally available to other Aastrom
employees. These benefit programs include the medical, dental
and vision insurance, long-term and short-term disability
insurance, life and accidental death and dismemberment
insurance, health and dependent care flexible spending accounts,
business travel insurance, and certain other benefits.
The 401(k) Plan and other generally available benefit programs
allow Aastrom to remain competitive for employee talent and
Aastrom believes that the availability of the benefit programs
generally enhances employee productivity and loyalty to Aastrom.
The main objectives of Aastroms benefits programs are to
give our employees access to quality healthcare, financial
protection from unforeseen events, assistance in achieving
retirement financial goals, enhanced health and productivity and
to provide support for global workforce mobility, in compliance
with applicable legal requirements. These generally available
benefits typically do not specifically factor into decisions
regarding an individual executives total compensation or
equity award package.
On an informal, annual basis, Aastrom benchmarks its overall
benefits programs against our peers. We also evaluate the
competitiveness of our 401(k) Plan as related to similar plans
of our peer group members by analyzing the dollar value to an
employee and the dollar cost to Aastrom for the benefits under
the applicable plan using a standard population of employees. We
analyze changes to our benefits programs in light of the overall
objectives of the program, including the effectiveness of the
retention and incentive features of such programs and our
targeted percentile range.
In fiscal year 2007, Aastrom provided certain relocation and
other benefits to Mr. Dunbar. Mr. Dunbars
relocation was made at the request of Aastrom in connection with
the commencement of his service. These benefits, which are
customary benefits provided to other employees, included
(i) housing, transportation, moving and other living
expense allowances; and (ii) tax equalization such that
Mr. Dunbar will not pay any more or less income tax had he
not accepted this benefit.
16
Compensation
of Chief Executive Officer
During fiscal year 2007, Mr. Dunbar received a salary of
$359,375. In setting Mr. Dunbars salary, target bonus
and equity compensation awards, the Committee relied on
market-competitive pay data and the strong belief that the Chief
Executive Officer significantly and directly influences
Aastroms overall performance. The Committee also took into
consideration the overall compensation policies discussed above.
Mr. Dunbar was not eligible to receive a bonus during the
fiscal year. He was granted (i) an option to purchase
2,500,000 shares of Aastrom Common Stock at an exercise
price of $1.38, the fair market value of Aastrom Common Stock on
the date of grant as initial grant as of the first date of his
employment. 2,000,000 shares were time based shares and
500,000 shares are performance shares as discussed above
under Long-Term Incentive Compensation. Mr. Dunbars
moving and relocation allowances for fiscal year 2007 was
$59,737.
Accounting
and Tax Considerations
In designing its compensation programs, Aastrom takes into
consideration the accounting and tax effect that each element
will or may have on Aastrom and the executive officers and other
employees as a group. Aastrom aims to keep the expense related
to its compensation programs as a whole within certain levels.
When determining how to apportion between differing elements of
compensation, the goal is to meet Aastroms objectives
while maintaining cost neutrality. For instance, if Aastrom
increases benefits under one program resulting in higher
compensation expense, Aastrom may seek to decrease costs under
another program in order to avoid compensation expense that is
above the desired level. Aastrom recognizes a charge to expenses
for accounting purposes when either stock options or restricted
stock are granted. Aastrom also considered that the 401(k) plan
provides tax-advantaged retirement planning vehicles for our
executives.
In addition, Aastrom has not provided any executive officer or
director with a
gross-up or
other reimbursement for tax amounts the executive might pay
pursuant to Section 280G or Section 409A of the
Internal Revenue Code. Section 280G and related Internal
Revenue Code sections provide that executive officers, directors
who hold significant shareholder interests and certain other
service providers could be subject to significant additional
taxes if they receive payments or benefits in connection with a
change in control of Aastrom that exceeds certain limits, and
that Aastrom or its successor could lose a deduction on the
amounts subject to the additional tax.
In determining which elements of compensation are to be paid,
and how they are weighted, Aastrom also takes into account
whether a particular form of compensation will be considered
performance-based compensation for purposes of
Section 162(m) of the Internal Revenue Code. Under
Section 162(m), Aastrom generally receives a federal income
tax deduction for compensation paid to any of its named
executive officers only if the compensation is less than
$1 million during any fiscal year or is
performance-based under Section 162(m). The
Compensation Plan permits our Committee to pay compensation that
is performance-based and thus fully tax-deductible
by Aastrom. Our Committee currently intends to continue seeking
a tax deduction for all of Aastroms executive
compensation, to the extent we determine it is in the best
interests of Aastrom. The stock options granted to our executive
officers in fiscal year 2007 are intended to qualify as
performance-based compensation under Section 162(m).
17
REPORT OF
THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
The Compensation Committee reviewed and discussed the
Compensation Discussion and Analysis with management. Based on
our review and discussions, the Compensation Committee
recommended to the Board of Directors that the Compensation
Discussion and Analysis be included in Aastroms 2007 proxy
statement.
COMPENSATION
COMMITTEE
Alan L. Rubino, Chair
Timothy M. Mayleben
Susan L. Wyant
18
Summary
Compensation Table
The following table summarizes all compensation awarded to,
earned by or paid to the Companys chief executive officer,
his predecessor who served as CEO for a portion of the fiscal
year, chief financial officer and two other most highly
compensated executive officers (collectively, the named
executive officers) during fiscal year 2007. You should
refer to the section entitled Compensation Discussion and
Analysis of this proxy statement to understand the
elements used in setting the compensation for our named
executive officers. A narrative description of the material
factors necessary to understand the information in the table is
provided below.
2007
SUMMARY COMPENSATION TABLE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non- Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
Incentive Plan
|
|
|
All Other
|
|
|
|
|
Name and Principal Position(1)
|
|
Year
|
|
|
Salary ($)
|
|
|
Awards ($)
|
|
|
Awards ($)
|
|
|
Compensation ($)(2)
|
|
|
Compensation ($)
|
|
|
Total ($)
|
|
|
George W. Dunbar,
|
|
|
2007
|
|
|
$
|
359,375
|
|
|
|
|
|
|
$
|
1,066,393
|
|
|
|
|
|
|
$
|
80,381
|
|
|
$
|
1,506,149
|
|
President and CEO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gerald D. Brennan,
|
|
|
2007
|
|
|
$
|
230,208
|
|
|
|
|
|
|
$
|
156,730
|
|
|
|
|
|
|
$
|
27,287
|
|
|
$
|
414,225
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert J. Bard, VP,
|
|
|
2007
|
|
|
$
|
217,494
|
|
|
$
|
15,441
|
|
|
$
|
125,860
|
|
|
|
|
|
|
$
|
11,224
|
|
|
$
|
370,019
|
|
Regulatory/
Clinical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R. Douglas Armstrong,
|
|
|
2007
|
|
|
$
|
511,328
|
|
|
$
|
3,673
|
|
|
$
|
1,885
|
|
|
|
|
|
|
$
|
67,203
|
|
|
$
|
584,089
|
|
Chairman,
Board of Directors
and Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Elmar R. Burchardt,
|
|
|
2007
|
|
|
$
|
187,271
|
|
|
|
|
|
|
$
|
91,820
|
|
|
|
|
|
|
$
|
69,146
|
|
|
$
|
348,237
|
|
VP, Medical Affairs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
In July 2006 Mr. Dunbar became President and CEO;
Dr. Armstrong resigned from his position as Chief Executive
Officer. In September 2007 Mr. Bard resigned. |
|
(2) |
|
The Board of Directors has determined that the non-equity
incentive plan bonuses for fiscal year 2007 are currently not
calculable. It is expected that a final determination will be
made on or before December 31, 2007. If these bonuses are
determined to be payable, the Company will disclose such amounts
in a Current Report on
Form 8-K
filed with the SEC. |
Salary. The salary column represents the base
salary earned by the named executive officer during fiscal year
2007. Dr. Armstrong received $496,378 in severance payments
during fiscal year 2007 pursuant to a Board approved agreement
covering the transition of his CEO responsibilities following
13 years of service.
Stock Awards. The stock awards column
represents the dollar amount of share-based compensation expense
recognized in fiscal year 2007 for restricted stock awards
granted to each of the named executive officers and share-based
compensation recognized in fiscal year 2007 relating to the
equity-based portions of our 2004 Plan. This compensation was
recognized for financial statement reporting purposes in
accordance with SFAS No. 123(R) (disregarding
forfeiture assumptions). For a discussion of the assumptions
used in calculating the dollar amount recognized, see
Note 3 to our consolidated financial statements in our
annual report on
Form 10-K
for fiscal year 2007 accompanying this proxy statement.
Option Awards. The option awards column
represents the dollar amount of share-based compensation expense
recognized in fiscal year 2007 for stock option awards granted
to each of the named executive officers for financial statement
reporting purposes in accordance with SFAS No. 123(R)
(disregarding forfeiture assumptions). For a discussion of the
assumptions used in calculating the dollar amount recognized,
see Note 3 to our consolidated financial statements in our
annual report for fiscal year 2007 accompanying this proxy
statement.
19
All Other Compensation. The all other
compensation column includes the following:
|
|
|
|
|
Aastrom contributions of $11,510 to Mr. Brennans
401(k) Supplemental Retirement Plan; $9,375 to
Mr. Dunbars 401(k) Supplemental Retirement Plan.
Dr. Burchardt and Mr. Bard did not participate in the
Companys 401(k) Supplemental Retirement Plan;
|
|
|
|
Payments for moving and relocation to Mr. Dunbar in the
amount of $59,737 and Dr. Burchardt in the amount of
$68,129 (including tax
gross-ups
for the payment of taxes);
|
|
|
|
Vacation payout of $52,086 to Dr. Armstrong upon his
resignation from the Company.
|
No named executive officers received perquisites having a value
of $10,000 or more. All other compensation also includes
medical, dental and vision premiums paid on behalf of the named
executive officers who have elected these benefits. These
benefits are offered to all full-time Aastrom employees.
Grants of
Plan-Based Awards
The following table summarizes all plan-based award grants to
each of the named executive officers during fiscal year 2007.
You should refer to the Compensation Discussion and Analysis
sections entitled Base Salary and Annual Incentive
Opportunities and Long-Term Incentive
Compensation to understand how plan-based awards are
determined. A narrative description of the material factors
necessary to understand the information in the table is provided
below.
2007
GRANTS OF PLAN-BASED AWARDS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option
|
|
|
|
|
|
Grant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Exercise
|
|
|
Date Fair
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
or Base
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
Price of
|
|
|
Stock and
|
|
|
|
|
|
|
Estimated Future Payouts Under Non-Equity Incentive Plan
Awards
|
|
|
Estimated Future Payouts Under Equity Incentive Plan
Awards
|
|
|
Under-lying
|
|
|
Option
|
|
|
Option
|
|
|
|
Grant
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Options
|
|
|
Awards
|
|
|
Awards
|
|
Name
|
|
Date
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
(#)
|
|
|
(#)
|
|
|
(#)
|
|
|
(#)
|
|
|
($)
|
|
|
($)
|
|
|
George W. Dunbar
|
|
|
11/2/2006
|
|
|
|
|
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7/17/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
$
|
1.38
|
|
|
$
|
1,899,600
|
|
|
|
|
7/17/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
|
|
|
|
$
|
1.38
|
|
|
$
|
446,044
|
|
Gerald D. Brennan
|
|
|
11/2/2006
|
|
|
|
|
|
|
$
|
70,125
|
|
|
$
|
70,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9/7/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
219,600
|
|
|
$
|
1.15
|
|
|
$
|
172,935
|
|
|
|
|
11/2/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
280,400
|
|
|
|
280,400
|
|
|
|
|
|
|
$
|
1.53
|
|
|
$
|
272,336
|
|
Elmar R. Burchardt
|
|
|
11/2/2006
|
|
|
|
|
|
|
$
|
69,360
|
|
|
$
|
69,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9/7/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250,000
|
|
|
$
|
1.15
|
|
|
$
|
196,875
|
|
Robert J. Bard
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9/7/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
218,400
|
|
|
$
|
1.15
|
|
|
$
|
171,990
|
|
Estimated Future Payouts Under Non-Equity Incentive Plan
Awards. Amounts in these columns represent future
cash payments under the Aastrom Biosciences Amended Employee
Compensation Guidelines (Compensation Guidelines).
The Board of Directors has determined that the non-equity
incentive plan bonuses for fiscal year 2007 are currently not
calculable. It is expected that a final determination will be
made on or before December 31, 2007. If these bonuses are
determined to be payable, the Company will disclose such amounts
in a Current Report on
Form 8-K
filed with the SEC.
Estimated Future Payouts Under Equity Incentive Plan
Awards. Amounts in this column represent grants
of performance-based stock options. These performance options
have a 10 year life and exercise prices equal to the fair
value of our stock at the grant date. Vesting of these
performance options is dependent on (i) the passage of time
subsequent to the grant date and (ii) meeting certain
performance conditions, which relate to our progress in our
clinical trial programs, and which were established by the Board
of Directors. The Board of Directors will determine if the
performance conditions have been met.
20
All Other Option Awards/Exercise or Base Price of Option
Awards. The exercise or base price of all option
awards is the closing market price of Aastrom Biosciences common
stock on the date of grant. These were granted with exercise
prices equal to the fair value of the Companys stock at
the grant date, vest over four years (other than non-employee
director options which vest over one year) and have lives of ten
years.
Grant Date Fair Value of Stock and Option
Awards. This column represents the grant date
fair value of each equity award granted in fiscal year 2007
computed in accordance with SFAS No. 123(R). For a
discussion of the assumptions we use in calculating the amount
recognized, see Note 3 to our consolidated financial
statements in our Annual Report on
Form 10-K
for fiscal year 2007 accompanying this proxy statement.
Outstanding
Equity Awards at Fiscal Year End
The table below reflects all outstanding equity awards made to
each of the named executive officers that are outstanding at the
end of fiscal year 2007.
OUTSTANDING
EQUITY AWARDS AT JUNE 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards:
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Market
|
|
|
|
Number of
|
|
|
Number of
|
|
|
Number of
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
Value of
|
|
|
|
Securities
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
Units of
|
|
|
Shares or
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
Stock That
|
|
|
Units of
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
Option
|
|
|
Have Not
|
|
|
Stock That
|
|
|
|
Options (#)
|
|
|
Options (#)
|
|
|
Unearned
|
|
|
Exercise
|
|
|
Expiration
|
|
|
Vested
|
|
|
Have Not
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable(1)
|
|
|
Options (#)
|
|
|
Price ($)
|
|
|
Date
|
|
|
(#)
|
|
|
Vested ($)
|
|
|
George W. Dunbar
|
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
|
$
|
1.38
|
|
|
|
7/17/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
$
|
1.38
|
|
|
|
7/17/2016
|
|
|
|
|
|
|
|
|
|
Gerald D. Brennan
|
|
|
52,500
|
|
|
|
67,500
|
|
|
|
|
|
|
$
|
2.94
|
|
|
|
8/11/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
219,600
|
|
|
|
|
|
|
$
|
1.15
|
|
|
|
9/7/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
280,400
|
|
|
$
|
1.53
|
|
|
|
11/2/2016
|
|
|
|
|
|
|
|
|
|
Elmar R. Burchardt
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
$
|
1.15
|
|
|
|
9/7/2016
|
|
|
|
|
|
|
|
|
|
Robert J. Bard
|
|
|
60,000
|
|
|
|
60,000
|
|
|
|
|
|
|
$
|
2.05
|
|
|
|
5/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
218,400
|
|
|
|
|
|
|
$
|
1.15
|
|
|
|
9/7/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,075
|
|
|
$
|
20,200
|
|
R. Douglas Armstrong
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
$
|
2.94
|
|
|
|
9/27/2010
|
|
|
|
|
|
|
|
|
|
|
|
|
421,875
|
|
|
|
|
|
|
|
|
|
|
$
|
1.05
|
|
|
|
9/17/2011
|
|
|
|
|
|
|
|
|
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
$
|
0.38
|
|
|
|
8/22/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
125,000
|
|
|
|
12,500
|
|
|
|
|
|
|
$
|
1.64
|
|
|
|
9/18/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
206,250
|
|
|
|
93,750
|
|
|
|
|
|
|
$
|
0.73
|
|
|
|
8/12/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,763
|
|
|
|
61,322
|
|
|
|
|
(1) |
|
These options vest over a period of four years, with 25% vesting
on the first anniversary of the date of grant and 6.25% vesting
each quarter thereafter. |
Option
Exercises and Stock Vested
The table below includes information related to options
exercised by each of the named executive officers and their
restricted stock awards that have vested during fiscal year
2007. The table also includes the value realized for such
options and restricted stock awards. For options, the value
realized on exercise is equal to the difference between the
market price of the underlying shares at exercise and the
exercise price of the options. For stock awards, the value
realized on vesting is equal to the market price of the
underlying shares at vesting.
21
2007
OPTION EXERCISES AND STOCK VESTED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
Shares
|
|
|
|
|
|
|
of Shares
|
|
|
Value
|
|
|
Acquired
|
|
|
Value
|
|
|
|
Acquired on
|
|
|
Realized on
|
|
|
on Vesting
|
|
|
Realized on
|
|
Name
|
|
Exercise (#)
|
|
|
Exercise ($)
|
|
|
(#)
|
|
|
Vesting ($)
|
|
|
George W. Dunbar
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gerald D. Brennan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Elmar R. Burchardt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert J. Bard
|
|
|
|
|
|
|
|
|
|
|
5,025
|
|
|
$
|
5,879
|
|
R. Douglas Armstrong
|
|
|
|
|
|
|
|
|
|
|
15,254
|
|
|
$
|
17,847
|
|
Employment
Contracts and Termination of Employment and Change of Control
Arrangements
Aastrom has entered into at will employment agreements with all
of its executive officers, which provide either party with the
right to terminate the employment relationship (in some
instances subject to 14 days prior written notice if the
termination is without cause). These employment agreements
provide for annual review and adjustment of salaries and
customary fringe benefits, such as vacation and health insurance
available to other employees.
Under the employment agreement with Mr. Dunbar, he will be
eligible to receive a discretionary cash bonus (as a participant
in Aastroms existing cash performance bonus program) based
upon his performance, as determined by the Board of Directors,
for up to 40% of his base salary. He will also be entitled to
reimbursement of Relocation Costs (as defined in his
agreement), which will not exceed $75,000 without the prior
approval of Aastrom. Mr. Dunbar has been granted an initial
stock option to purchase 2,500,000 shares (with an exercise
price of $1.38, the fair market value on July 17, 2006,
which is the date of grant) of which
(a) 2,000,000 shares are subject to time vesting (with
25% vesting on the first anniversary and the remaining 75% to
vest monthly over the following three years), and
(b) 500,000 shares are subject to vesting based upon
performance objectives as well as time vesting over four years.
Additionally, beginning in September 2007, Mr. Dunbar will
receive annual stock option grants (targeted for
400,000 shares per year) subject to both the time vesting
and performance vesting. In the event of his termination by the
Company without Cause or by Mr. Dunbar for
Good Reason within one year following a Change
of Control (in each case, as those terms are defined in
the Agreement), the vesting of all his stock options will
accelerate, with all options becoming fully exercisable.
Additionally, if his employment is terminated by the Company
without Cause after July 14, 2007 or if he
terminates his employment for Good Reason, one half
of Mr. Dunbars unvested stock options will become
exercisable. If Mr. Dunbars employment is terminated
without Cause or if he terminates his employment for
Good Reason (in each case, other than in conjunction
with a Change of Control), he will be entitled to a
severance payment equal to one year of his annual base salary at
termination. If Mr. Dunbars employment is terminated
within one year following a Change in Control, he
will be entitled to: (a) if the termination is by the
Company and is without Cause, a severance payment equal to two
times his base salary at termination plus one times his targeted
annual cash bonus, or (b) if he terminates his employment
for Good Reason, a severance payment equal to his annual base
salary at termination, plus one-half of his targeted annual cash
bonus.
The employment agreements with Mr. Brennan,
Dr. Burchardt and Mr. Bard provide that each
individual will receive a severance payment of 6 months of
salary if he is terminated without cause or if he resigns for
good reason (as specified in the employment agreement) within
one year following a change of control.
In the event of a transfer of control of Aastrom, as defined in
the Companys stock option plan, Aastrom must cause any
successor corporation to assume the outstanding stock options or
substitute similar options for outstanding options. In the event
that any successor to Aastrom in a merger or consolidation will
not assume the options or substitute similar options, then the
options become exercisable in full and such options will be
terminated if not exercised prior to such merger or
consolidation. In general, options granted to executive officers
of Aastrom will become fully exercisable if such officer is
terminated following a transfer of control. Options granted to
non-employee directors under Aastroms stock option plans
will become fully vested and immediately exercisable upon a
transfer of control, as defined in the respective option plans.
22
In 2005, Dr. Armstrong requested the Governance Committee
to initiate a search for his replacement as Chief Executive
Officer, allowing him to transition out of day-to-day management
responsibilities. On December 27, 2005, Aastrom entered
into a Revised Employment Agreement with Dr. Armstrong to
provide for the continuation of his services pending the
retention of a new CEO. Aastrom retained a new CEO effective on
July 17, 2006, and since that time Dr. Armstrong has
served as a consultant. Under the terms of his Employment
Agreement, Dr. Armstrong will receive a payment of $638,200
made in various installments starting in July 2006 and
continuing through April 2008. Aastrom will also pay
Dr. Armstrong for the costs of his COBRA health insurance
coverage for twelve months following termination of his service
as CEO. The consulting agreement with Dr. Armstrong covers
transition services the Company may need above and beyond what
Dr. Armstrong is already required to provide. For the
period running through November 2, 2007, Dr. Armstrong
will provide assistance with management transition matters and
other services requested by Mr. Dunbar. Dr. Armstrong
will receive (i) a retainer of $5,000 per month for the
four months ending with October 2006, (ii) $2,000 for each
day Dr. Armstrong provides services under the consulting
agreement, and (iii) reimbursement of any reasonable
expenses incurred in providing these services, consistent with
the Companys customary expense reimbursement policies and
practices.
Termination
Following a Change of Control
The following table sets forth our lump-sum payment obligations
under the Employment Agreements upon a termination of the
employment of our named executive officers within one year
following a change in control and upon the occurrence of certain
other conditions. The table assumes termination on June 30,
2007 and payment of such termination obligations within a
reasonable time thereafter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
Name
|
|
Severance
|
|
|
Bonus
|
|
|
Acceleration(3)
|
|
|
Total
|
|
|
George W. Dunbar(1)
|
|
$
|
750,000
|
|
|
$
|
150,000
|
|
|
|
|
|
|
$
|
900,000
|
|
Gerald D. Brennan(2)
|
|
$
|
116,875
|
|
|
|
|
|
|
$
|
41,724
|
|
|
$
|
158,599
|
|
Elmar R. Burchardt(2)
|
|
$
|
115,600
|
|
|
|
|
|
|
$
|
47,500
|
|
|
$
|
163,100
|
|
Robert J. Bard(2)
|
|
$
|
110,026
|
|
|
|
|
|
|
$
|
41,496
|
|
|
$
|
151,522
|
|
Termination
without Cause or for Good Reason
The following table sets forth our lump-sum payment obligations
under the Employment Agreements upon a termination of the
employment of our named executive officers without cause or for
good reason and upon the occurrence of certain other conditions.
The table assumes termination on June 30, 2007 and payment
of such termination obligations within a reasonable time
thereafter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
Name
|
|
Severance
|
|
|
Bonus
|
|
|
Acceleration(3)
|
|
|
Total
|
|
|
George W. Dunbar(4)
|
|
$
|
375,000
|
|
|
$
|
75,000
|
|
|
|
|
|
|
$
|
450,000
|
|
Gerald D. Brennan(2)
|
|
$
|
116,875
|
|
|
|
|
|
|
|
|
|
|
$
|
116,875
|
|
Elmar R. Burchardt(2)
|
|
$
|
115,600
|
|
|
|
|
|
|
|
|
|
|
$
|
115,600
|
|
Robert J. Bard(2)
|
|
$
|
110,026
|
|
|
|
|
|
|
|
|
|
|
$
|
110,026
|
|
|
|
|
(1) |
|
If Mr. Dunbars employment is terminated within one
year following a change in control, he will be entitled to a
severance payment equal to two times his base salary, plus his
targeted annual cash bonus. |
(2) |
|
If Mr. Brennan, Dr. Burchardt or Mr. Bards
employment is terminated (with the exception of
cause), each will be entitled to a severance payment
equal to six months of their base salary. |
(3) |
|
If Mr. Dunbars employment is terminated (with the
exception of cause), the vesting of all of his stock
options will accelerate, with all options becoming fully
exercisable. At June 30, 2007, the intrinsic value of all
of Mr. Dunbars stock options was zero. No other named
executive officer has a stock option acceleration provision
included in their Employment Agreement. However, all employee
stock options granted September 2006 or later have a
double trigger provision whereby if an employee is
terminated within one year of a change in control the
vesting of all stock options will accelerate, with all stock
options becoming fully exercisable. At June 30, 2007, the
intrinsic value of Mr. Brennan, Dr. Burchardt and
Mr. Bards stock options are included above. |
(4) |
|
If Mr. Dunbars employment is terminated without cause
or for good reason, he will be entitled to a severance payment
equal to his base salary at termination, plus one-half his
targeted annual cash bonus. |
23
Compensation
of Directors
The Director Compensation table reflects all compensation
awarded to, earned by or paid to the Companys non-employee
directors during fiscal year 2007.
2007
DIRECTOR COMPENSATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
or Paid
|
|
|
Stock
|
|
|
Option
|
|
|
Compensation
|
|
|
|
|
Name
|
|
in Cash ($)
|
|
|
Awards ($)
|
|
|
Awards ($)
|
|
|
($)
|
|
|
Total ($)
|
|
|
R. Douglas Armstrong(1)
|
|
$
|
8,125
|
|
|
$
|
18,088
|
|
|
$
|
13,165
|
|
|
$
|
304,085
|
|
|
$
|
343,463
|
|
Timothy M. Mayleben
|
|
$
|
37,500
|
|
|
|
|
|
|
$
|
69,141
|
|
|
|
|
|
|
$
|
106,641
|
|
Alan L. Rubino
|
|
$
|
36,250
|
|
|
|
|
|
|
$
|
69,600
|
|
|
|
|
|
|
$
|
105,850
|
|
Nelson M. Sims
|
|
$
|
35,000
|
|
|
|
|
|
|
$
|
55,010
|
|
|
|
|
|
|
$
|
90,010
|
|
Stephen G. Sudovar
|
|
$
|
35,000
|
|
|
|
|
|
|
$
|
66,944
|
|
|
|
|
|
|
$
|
101,944
|
|
Susan L. Wyant
|
|
$
|
36,875
|
|
|
|
|
|
|
$
|
68,763
|
|
|
|
|
|
|
$
|
105,638
|
|
Robert L. Zerbe
|
|
$
|
30,000
|
|
|
|
|
|
|
$
|
63,028
|
|
|
|
|
|
|
$
|
93,028
|
|
|
|
|
(1) |
|
Dr. Armstrong concluded his services as a member of the
Board of Directors as of November 2, 2006. During fiscal
year 2007, Dr. Armstrong was an employee from July 1 to
July 17, 2006; for total compensation as an employee see
the Summary Compensation Table. |
Fees Earned or Paid in Cash. Each nonemployee
director receives an annual fee of $25,000 paid in equal
quarterly increments. The chairperson of each standing committee
and the Lead Director each receives an additional annual fee of
$7,500 and each non-chair committee member receives an
additional annual fee of $5,000, payable quarterly. Directors
are no longer paid a separate amount for each board or committee
meeting attended.
Stock and Option Awards. Commencing in
November 2006, each nonemployee director who continues to serve
beyond an Annual Meeting of Shareholders will receive a stock
option to purchase 55,000 shares granted on the date of
each Annual Meeting of Shareholders, with an exercise price
equal to the fair market value of the common stock on the date
of grant, vesting in equal quarterly increments over a period of
one year. Newly elected directors joining the board during the
period between Annual Meetings of Shareholder will receive a
grant for a pro rata amount of the 55,000 shares subject to
option (reflecting the period of time until the next Annual
Meeting of Shareholders). Outside directors will no longer
receive grants of restricted stock. These equity grants will be
made under the terms of the existing equity compensation plans,
as previously approved by the shareholders. Amounts in the stock
and option awards columns represent the share-based compensation
expense recognized in fiscal year 2007 for financial statement
reporting purposes in accordance with SFAS No. 123(R)
(disregarding forfeiture assumptions). For a discussion of the
assumptions used in calculating the dollar amount recognized,
see Note 3 to our consolidated financial statements in our
annual report on
Form 10-K
for fiscal year 2007 accompanying this proxy statement.
All Other Compensation. All other compensation
includes consulting fees and share-based compensation expense
recognized in fiscal year 2007 for financial statement reporting
purposes in accordance with SFAS No. 123(R)
(disregarding forfeiture assumptions). For a discusiion of the
assumptions used in calculating the dollar amount recognized,
see Note 3 to our consolidated financial statements in our
Annual Report on
Form 10-K
for fiscal year 2007 accompanying this proxy statement.
Option Holdings. Non-employee directors held
the following stock options as of June 30, 2007:
|
|
|
|
|
|
|
Stock Options
|
|
|
Timothy M. Mayleben
|
|
|
97,000
|
|
Alan L. Rubino
|
|
|
97,000
|
|
Nelson M. Sims
|
|
|
62,500
|
|
Steven G. Sudovar
|
|
|
97,000
|
|
Susan L. Wyant
|
|
|
127,000
|
|
Robert L. Zerbe
|
|
|
73,400
|
|
24
Compensation
Committee Interlocks and Insider Participation in Compensation
Decisions
No member of the Compensation Committee is, or ever has been, an
officer or employee of the Company.
Certain
Relationships and Related Party Transactions
The Board is committed to upholding the highest legal and
ethical conduct in fulfilling its responsibilities and
recognizes that related party transactions can present a
heightened risk of potential or actual conflicts of interest.
Accordingly, as a general matter, it is Aastroms
preference to avoid related party transactions.
Aastroms Audit Committee Charter requires that members of
the Audit Committee, all of whom are independent directors,
review and approve all related party transactions for which such
approval is required under applicable law, including SEC and
Nasdaq rules. Current SEC rules define a related party
transaction to include any transaction, arrangement or
relationship in which Aastrom is a participant and in which any
of the following persons has or will have a direct or indirect
interest:
|
|
|
|
|
an executive officer, director or director nominee of Aastrom;
|
|
|
|
any person who is known to be the beneficial owner of more than
5% of Aastroms Common Stock;
|
|
|
|
any person who is an immediate family member (as defined under
Item 404 of
Regulation S-K)
of an executive officer, director or director nominee or
beneficial owner of more than 5% of Aastroms common stock;
|
|
|
|
any firm, corporation or other entity in which any of the
foregoing persons is employed or is a partner or principal or in
a similar position or in which such person, together with any
other of the foregoing persons, has a 5% or greater beneficial
ownership interest.
|
In addition, the Audit Committee is responsible for reviewing
and investigating any matters pertaining to the integrity of
management, including conflicts of interest and adherence to
Aastroms Code of Business Conduct and Ethics. Under this
code, directors, officers and all other employees are expected
to avoid any relationship, influence or activity that would
cause or even appear to cause a conflict of interest.
Aastroms Corporate Governance Guidelines require a
director to promptly disclose to the Board any potential or
actual conflict of interest. Under these Guidelines, the Board
will determine an appropriate resolution on a
case-by-case
basis. All directors must recuse themselves from any discussion
or decision affecting their personal, business or professional
interests.
All related party transactions shall be disclosed in
Aastroms applicable filings with the Securities and
Exchange Commission as required under SEC rules.
There were no such reportable relationships or related party
transactions during fiscal year 2006.
Section 16(a)
Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as
amended, requires Aastroms executive officers, directors
and persons who beneficially own more than 10% of Aastroms
common stock to file initial reports of ownership and reports of
changes in ownership with the SEC. Such persons are required by
the SEC regulations to furnish Aastrom with copies of all
Section 16(a) forms filed by such persons.
Based solely on Aastroms review of such forms furnished to
it and written representations from certain reporting persons,
Aastrom believes that all filing requirements applicable to its
executive officers, directors and more than 10% shareholders
were complied with.
25
REPORT OF
THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
The Audit Committee oversees Aastroms financial reporting
process on behalf of the Board of Directors. Management has the
primary responsibility for the financial statements and the
reporting process, including internal control systems.
PricewaterhouseCoopers LLP is responsible for expressing an
opinion as to the conformity of our audited financial statements
with generally accepted accounting principles and an opinion on
our internal control over financial reporting. The Audit
Committee acts pursuant to a written charter that has been
adopted by the Board of Directors.
The Audit Committee consists of three (four until November
2006) directors each of whom, in the judgment of the Board,
is an independent director as defined in
Rule 4200(a)(15) of the NASD listing standards. For the
fiscal year 2007, the members of the Audit Committee were
Timothy M. Mayleben, Alan L. Rubino and, Nelson M. Sims. Stephen
G. Sudovar was a member of the Audit Committee until he was
appointed Chairman in November 2006.
The Committee has discussed and reviewed with the auditors all
matters required to be discussed by the Statement on Auditing
Standards No. 61 (Communication with Audit Committees), as
amended. The Committee has met with PricewaterhouseCoopers LLP,
with and without management present, to discuss the overall
scope of the PricewaterhouseCoopers LLP audit, the results of
its audits, its evaluations of Aastroms internal controls
and the overall quality of its financial reporting. The Audit
Committee reviewed the Companys financial statements and
discussed them with management and with PricewaterhouseCoopers
LLP.
The Audit Committee has received from the auditors a formal
written statement describing all relationships between the
auditors and Aastrom that might bear on the auditors
independence consistent with Independence Standards Board
Standard No. 1 (Independence Discussions with Audit
Committees), discussed with the auditors any relationships that
may impact their objectivity and independence, and satisfied
itself as to the auditors independence.
Based on the review and discussions referred to above, the
Committee recommended to the Board of Directors that
Aastroms audited financial statements be included in
Aastroms Annual Report on
Form 10-K
for the fiscal year ended June 30, 2007.
AUDIT
COMMITTEE
Timothy M. Mayleben, Chair
Alan L. Rubino
Nelson M. Sims
26
REPORT OF
THE CORPORATE GOVERNANCE AND
NOMINATING COMMITTEE OF THE BOARD OF DIRECTORS
The Corporate Governance and Nominating Committee (the
Governance Committee) consists of directors who meet
applicable independence criteria established by the NASD listing
standards. For the fiscal year ended June 30, 2007, the
members of the Governance Committee were Nelson M. Sims, Susan
L. Wyant and Robert L. Zerbe. Stephen G. Sudovar was a member of
the Governance Committee until he was appointed Chairman in
November 2006. The Governance Committee acts pursuant to a
written charter that has been adopted by the Board of Directors.
The primary responsibilities of the Governance Committee are to
(i) identify, review and evaluate individuals qualified to
become Board members; (ii) recommend nominees to the Board
and to each Committee of the Board; (iii) recommend
corporate governance principles, codes of conduct and compliance
mechanisms applicable to the Company, and monitor compliance
with them; and (iv) assist the Board in its reviews of the
performance of the Board and each Committee.
During its meetings in the last fiscal year, the Governance
Committee identified desired Board skills and attributes,
reviewed potential candidates for the Board and periodically
assessed the Companys compliance with applicable NASD
listing requirements. The Governance Committee has also
developed and assisted in the implementation of various
corporate governance policies and procedures. The Governance
Committee also establishes policies and procedures for the
Companys Disclosure Committee and has established
procedures for confidential submission of claims or situations
reported pursuant to the Companys whistle
blowing policy, including establishing a confidential
telephone mailbox for anyone to call to raise an issue. The
Committee has monitored that mailbox since its establishment and
there have been no calls received. The Committee has also
reviewed compliance with Company policies regarding trading in
Aastroms shares by officers, directors and senior
management personnel. The Governance Committee also assisted the
Board in its annual self-evaluation, as well as the evaluation
of the performance of other Committees.
CORPORATE
GOVERNANCE AND NOMINATING
COMMITTEE
Susan L. Wyant, Chair
Nelson M. Sims
Robert L. Zerbe
27
SHAREHOLDER
PROPOSALS TO BE PRESENTED
AT NEXT ANNUAL MEETING
Under Aastroms bylaws, in order for business to be
properly brought before a meeting by a shareholder, such
shareholder must have given timely notice thereof in writing to
the Corporate Secretary of Aastrom. To be timely, such notice
must be received at Aastroms principal executive offices
not less than 120 calendar days in advance of the one year
anniversary of the date Aastroms proxy statement was
released to shareholders in connection with the previous
years annual meeting of shareholders, except that
(i) if no annual meeting was held in the previous year,
(ii) if the date of the annual meeting has been changed by
more than thirty calendar days from the date contemplated at the
time of the previous years proxy statement or
(iii) in the event of a special meeting, then notice must
be received not later than the close of business on the tenth
day following the day on which notice of the date of the meeting
was mailed or public disclosure of the meeting date was made.
Proposals of shareholders intended to be presented at the next
annual meeting of the shareholders of Aastrom must be received
by Aastrom at its offices at 24 Frank Lloyd Wright Drive, Lobby
K, Ann Arbor, Michigan 48105, no later than June 11, 2008.
Such shareholder proposals may also be included in
Aastroms proxy statement if they also satisfy the
conditions established by the Securities and Exchange Commission
for such inclusion.
TRANSACTION
OF OTHER BUSINESS
At the date of this Proxy Statement, the only business which the
Board of Directors intends to present or knows that others will
present at the meeting is as set forth above. If any other
matter or matters are properly brought before the meeting, or
any adjournment thereof, it is the intention of the persons
named in the accompanying form of proxy to vote the proxy on
such matters in accordance with their best judgment.
By order of the Board of Directors,
Gerald D. Brennan, Jr.
Corporate Secretary, Vice President,
Administrative & Financial
Operations and Chief Financial Officer
October 11, 2007
28
ELECTRONIC
DELIVERY OF FUTURE ANNUAL MEETING MATERIALS
Aastrom offers shareholders the choice to receive future annual
reports and proxy materials electronically over the internet
instead of receiving paper copies through the mail. This will
save Aastrom the cost of printing and mailing them. Whether you
hold shares registered directly in your name, or through a
broker or bank, you can enroll for future electronic delivery of
proxy statements and annual reports by following these easy
steps:
|
|
|
|
|
Go to our website at www.aastrom.com;
|
|
|
|
Click on Investors;
|
|
|
|
In the Shareholder Services section, click on
Shareholder Electronic Delivery; and
|
|
|
|
Follow the prompts to submit your consent for electronic
delivery.
|
Generally, brokers and banks offering this choice require that
shareholders vote through the internet in order to enroll.
Street name shareholders whose broker or bank is not included in
this website are encouraged to contact their broker or bank and
ask about the availability of electronic delivery. As with all
internet usage, the user must pay all access fees and telephone
charges. You may view this years annual report and proxy
materials at www.aastrom.com/annuals.
29
AASTROM BIOSCIENCES, INC. Proxy for Annual Meeting of Shareholders Solicited by the Board of
Directors The undersigned hereby appoints George W. Dunbar and Gerald D. Brennan, Jr., and each of
them, with full power of substitution to represent the undersigned and to vote all of the shares of
stock of Aastrom Biosciences, Inc. (the Company) which undersigned is entitled to vote at the
Annual Meeting of Shareholders of the Company to be held at Aastrom Biosciences, Inc.
headquarters, Ann Arbor, Michigan on Wednesday, November 7, 2007 at 9:00 a.m., and at any
adjournment thereof (i) as hereinafter specified upon the proposals listed on the reverse side and
as more particularly described in the Companys Proxy Statement, receipt of which is hereby
acknowledged, and (ii) in their discretion upon such other matters as may properly come before the
meeting. The shares represented hereby shall be voted as specified. If no specification is made,
such shares shall be voted FOR proposal 1 and proposal 2. (CONTINUED AND TO BE SIGNED ON THE
REVERSE SIDE) |
VOTE BY INTERNET www.proxyvote.com Use the Internet to transmit your voting instructions and for
electronic delivery of information up until 11:59 P.M. Eastern Time the day before the AASTROM
BIOSCIENCES, INC. cut-off date or meeting date. Have your proxy card in hand when you 24 FRANK
LLOYD WRIGHT DRIVE LOBBY K access the web site and follow the instructions to obtain your records
and to create an electronic voting instruction form. ANN ARBOR, MI 48105 ELECTRONIC DELIVERY OF
FUTURE SHAREHOLDER COMMUNICATIONS If you would like to reduce the costs incurred by Aastrom
Biosciences, Inc. in mailing proxy materials, you can consent to receiving all future proxy
statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up
for electronic delivery, please follow the instructions above to vote using the Internet and, when
prompted, indicate that you agree to receive or access shareholder communications electronically in
future years. VOTE BY PHONE 1-800-690-6903 Use any touch-tone telephone to transmit your voting
instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have
your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and
date your proxy card and return it in the postage-paid envelope we have provided or return it to
Aastrom Biosciences, Inc., c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK
BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: ASTRM1 KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY
CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY AASTROM BIOSCIENCES,
INC. A vote FOR the following proposals is recommended by the Board of Directors: Vote On Directors
For Withhold For All To withhold authority to vote for any individual All All Except nominee(s),
mark For All Except and write the 1. ELECTION OF DIRECTORS number(s) of the nominee(s) on the
line below. Nominees: 01) George W. Dunbar 0 0 0 02) Susan L. Wyant 03) Robert L. Zerbe Vote On
Proposal For Against Abstain 2. To ratify the appointment of PricewaterhouseCoopers LLP as
Aastroms Independent Registered Public Accounting Firm for 0 0 0 the fiscal year ending June 30,
2008. Even if you are planning to attend the meeting in person, you are urged to sign and mail the
Proxy in the return envelope so that your stock may be represented at the meeting. Sign exactly as
your name(s) appear(s) on your stock certificate. If shares of stock stand of record in the names
of two or more persons or in the name of husband and wife, whether as joint tenants or otherwise,
both or all of such persons should sign the above Proxy. If shares of stock are held of record by
a corporation, the Proxy should be executed by the President or Vice President and the Secretary or
Assistant Secretary, and the corporate seal should be affixed thereto. Executors or administrators
or other fiduciaries who execute the above Proxy for a deceased shareholder should give their
title. Please date the Proxy. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners)
Date |